ZyVersa Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ZyVersa Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($19.81M) | Nov 19, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($2.21M) | Nov 19, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.21M) | Aug 13, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($2.26M) | Aug 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($2.26M) | Nov 19, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.26M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.40M) | Nov 19, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($2.76M) | Nov 19, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.76M) | Aug 13, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($2.83M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($2.83M) | May 12, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($2.83M) | Nov 19, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($2.90M) | Nov 14, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($78.51M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($78.51M) | Aug 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($3.54M) | Aug 9, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($3.54M) | May 15, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($3.54M) | Nov 14, 2024 |
| Q3 | 2022 | Sep 30, 2022 | ($679.1K) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2022 | ($393.6K) | Aug 15, 2022 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($20.75M) | Nov 19, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.04M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.14M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.27M) | Nov 19, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.75M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($2.83M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($2.90M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($86.33M) | Aug 9, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.59M) | May 15, 2024 |
| Q3 | 2022 | Sep 30, 2022 | ($985.6K) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2022 | ($498.8K) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2022 | ($801.0K) | May 13, 2022 |
| Q3 | 2022 | Sep 30, 2021 | ($174) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($789) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($1.1K) | May 13, 2022 |